Uptake of genetic testing for cancer predisposition

Journal of Medical Genetics

Volumn 34, Issue 9, 1997, Pages 746-748

  Evans, D Gareth R ^a,b   Maher, Eamonn R ^c   Macleod, Rhona ^b   Davies, D Rhodri ^b   Craufurd, David ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer; DNA predictive testing; FAP; NF2; vHL

Indexed keywords

ADENOMATOUS POLYP; ADOLESCENT; ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CHILD; FAMILIAL CANCER; FAMILIAL POLYPOSIS; FEMALE; GENETIC SCREENING; HUMAN; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; REGISTER; SEX DIFFERENCE; UNITED KINGDOM; VON HIPPEL LINDAU DISEASE;

EID: 0030984038     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.34.9.746     Document Type: Article

References (16)

1. Huson SM, Harper PS, Compston DAS. Von Recklinghausen neurofibromatosis. Brain 1988;111:1355-81.
2. Evans DGR, Huson S, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
3. Evans DGR, Guy SP, Armstrong J, et al. Non penetrance and late appearance of polyps in families with familial adenomatous polyposis. Gut 1993;34:1389-93.
4. Maher ER, Iselius h, Yates JRW, et al. Von Hippel Lindau disease: a genetic study. J Med Genet 1991;28:443-7.
5. Varley JM, McGown G, Thorncroft M, et al. Germline mutations of TP53 in Li Fraumeni families: an extended study of 39 families. Cancer Res (in press).
6. Craufurd D, Kerzin-Storrer L, Dodge A, Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 1989;ii:603-5.
7. Eeles R, El-Abdi S, Sodha H, Varley J, Evans DGR, Pritchard-Jones K. Predictive p53 testing in children: a suggested model. In preparation.
8. Harper PS. Insurance and genetic testing. Lancet 1993;341:224-7.
9. MacDonald F, Morton DG, Rindl PM, et al. Predictive diagnosis of familial adenomatous polyposis with linked DNA markers: population based study. BMJ 1992;304:869-72.
10. Struewing JP, Lerman C, Kase RG, Giambaressi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 1995;4:169-73.
11. Lynch HT, Watson P, Conway TA, et al. DNA screening for breast/ovarian cancer susceptibility based on linked markers. Arch Intern Med 1993;153:1979-87.
12. Binchy A, Evans DGR, Eng C, Hendy-Ibbs P, Ponder BAJ, Craufurd D. Factors influencing uptake of predictive testing for BRCA1 in five large BRCA1 linked families. (Submitted.)
13. Watson M, Murday V, Lloyd S, Ponder B, Averill D, Eeles R. Genetic testing in breast/ovarian cancer (BRCA1) families. Lancet 1995;346:583.
14. Schneider KA, Patenaude AF, Garber JE. Testing for cancer genes: decisions, decisions. Nat Med 1995;1:302-3.
15. Varley JM, Tricker KJ, Thorncroft M, et al. An extended Li Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 1995;32:942-5.
16. The genetic testing of children. Report of a Working Party of the Clinical Genetics Society (UK). Chairman Dr A Clarke. J Med Genet 1994;31:785-97.